NCT02970539View on ClinicalTrials.gov

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 8, 2016

Primary Completion Date

March 27, 2019

Study Completion Date

December 31, 2022

Conditions
Gastric CancerEsophageal CancerGastro-esophageal Cancer
Interventions
DRUG

Oraxol

Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.

DRUG

Ramucirumab

Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL

Trial Locations (5)

11490

Tri-Service General Hospital, Taipei

26546

Lotung Poh-Ai Hospital, Yilan

78229

CTRC-UT, San Antonio

Unknown

China Medical University Hospital, Taichung

Taipei Veterans General Hospital, Taipei

Sponsors

Lead Sponsor

Athenex, Inc.
All Listed Sponsors
lead

Athenex, Inc.

INDUSTRY